Zobrazeno 1 - 10
of 134
pro vyhledávání: '"Camorani, P"'
Autor:
Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi, Laura Cerchia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/caa53223c21940d98c00a0f82a75300b
Autor:
Simona Camorani, Alessandra Caliendo, Elena Morrone, Lisa Agnello, Matteo Martini, Monica Cantile, Margherita Cerrone, Antonella Zannetti, Massimo La Deda, Monica Fedele, Loredana Ricciardi, Laura Cerchia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-19 (2024)
Abstract Background Based on the established role of cancer-stroma cross-talk in tumor growth, progression and chemoresistance, targeting interactions between tumor cells and their stroma provides new therapeutic approaches. Dual-targeted nanotherape
Externí odkaz:
https://doaj.org/article/f2b432946e7242598a6cb68ee4977e6a
Autor:
Luis Exequiel Ibarra, Simona Camorani, Lisa Agnello, Emilia Pedone, Luciano Pirone, Carlos Alberto Chesta, Rodrigo Emiliano Palacios, Monica Fedele, Laura Cerchia
Publikováno v:
Pharmaceutics, Vol 16, Iss 10, p 1281 (2024)
In the original publication [...]
Externí odkaz:
https://doaj.org/article/fd50f27dd1d54313a3c82615bc13dcb3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lisa Agnello, Silvia Tortorella, Annachiara d’Argenio, Clarissa Carbone, Simona Camorani, Erica Locatelli, Luigi Auletta, Domenico Sorrentino, Monica Fedele, Antonella Zannetti, Mauro Comes Franchini, Laura Cerchia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-17 (2021)
Abstract Background Management of triple-negative breast cancer (TNBC) is still challenging because of its aggressive clinical behavior and limited targeted treatment options. Cisplatin represents a promising chemotherapeutic compound in neoadjuvant
Externí odkaz:
https://doaj.org/article/05d5a150966845deb9586192e9f1ca8b
Autor:
Lisa Agnello, Annachiara d’Argenio, Alessandra Caliendo, Roberto Nilo, Antonella Zannetti, Monica Fedele, Simona Camorani, Laura Cerchia
Publikováno v:
Cells, Vol 12, Iss 13, p 1809 (2023)
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes. Despite being initially responsive to chemotherapy, patients develop drug-resistant and metastatic tumors. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is
Externí odkaz:
https://doaj.org/article/b1552b1ea39c4b56ab858f724d653ff1
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 2, Iss 1, Pp 107-121 (2021)
The goal of an efficacious cancer therapy is to specifically target diseased cells at high accuracy while sparing normal, healthy cells. Over the past three decades, immunotherapy, based on the use of monoclonal antibodies (mAbs) directed against tum
Externí odkaz:
https://doaj.org/article/788f22147528424b8010d87ceeb4e1db
Autor:
Simona Camorani, Margherita Passariello, Lisa Agnello, Silvia Esposito, Francesca Collina, Monica Cantile, Maurizio Di Bonito, Ilya V. Ulasov, Monica Fedele, Antonella Zannetti, Claudia De Lorenzo, Laura Cerchia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-16 (2020)
Abstract Background Triple-negative breast cancer (TNBC) is a uniquely aggressive cancer with high rates of relapse due to resistance to chemotherapy. TNBC expresses higher levels of programmed cell death-ligand 1 (PD-L1) compared to other breast can
Externí odkaz:
https://doaj.org/article/911c06d557cc40be9d9119392620f362
Autor:
Simona Camorani, Silvia Tortorella, Lisa Agnello, Chiara Spanu, Annachiara d’Argenio, Roberto Nilo, Antonella Zannetti, Erica Locatelli, Monica Fedele, Mauro Comes Franchini, Laura Cerchia
Publikováno v:
Pharmaceutics, Vol 14, Iss 10, p 2225 (2022)
Small interfering RNA (siRNA) therapies require effective delivery vehicles capable of carrying the siRNA cargo into target cells. To achieve tumor-targeting, a drug delivery system would have to incorporate ligands that specifically bind to receptor
Externí odkaz:
https://doaj.org/article/64066776e9584aa0a1c8720dd5e37e99
Autor:
Simona Camorani, Ilaria Granata, Francesca Collina, Francesco Leonetti, Monica Cantile, Gerardo Botti, Monica Fedele, Mario Rosario Guarracino, Laura Cerchia
Publikováno v:
iScience, Vol 23, Iss 4, Pp - (2020)
Summary: Triple-negative breast cancer (TNBC) is a high heterogeneous group of tumors with a distinctly aggressive nature and high rates of relapse. So far, the lack of any known targetable proteins has not allowed a specific anti-tumor treatment. Th
Externí odkaz:
https://doaj.org/article/9ff46755f1b140d1aa2f78de9deccd9e